RaNA Raises $20.7M From Atlas, SR One, Monsanto, for RNA-Based Tech

Generations of high school kids have been taught that only about 3 percent of the human genome is actually useful—meaning it contains genes that code proteins—and the rest is “junk DNA.” Cambridge, MA-based RaNA Therapeutics was founded on the idea that the so-called junk is actually gold, because it contains a type of RNA that … Continue reading RaNA Raises $20.7M From Atlas, SR One, Monsanto, for RNA-Based Tech